US4442089A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for treating glaucoma with topical or systemic ACE inhibitor compositions
Assignee: ER Squibb and Sons LLC
•
Filing: 1982-07-06
•
Granted: 1984-04-10
•
Expires: 2002-07-06
Abstract
Abstract A method is provided for treating glaucoma by topical or systemic administration of an ACE inhibitor such as captopril.
Inventors
- 👤 Zola P. Horovitz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-10 02:17
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/66; A61K31/675; A61K31/33; A61K31/395; A61K31/40; A61K38/00; A61K38/16; A61K38/55; A61K38/556; A61P; A61P27/00; A61P27/02; A61P27/06; C; C07; C07F; C07F9/00; C07F9/02; C07F9/547; C07F9/553; C07F9/572
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
50 words
A method for treating glaucoma or lowering intraocular pressure in a mammalian species, which comprises topically or systemically administering an effective amount of an angiotensin converting enzyme inhibitor selected from the group consisting of a substituted proline derivative, a carboxyalkyl dipeptide derivative, a phosphinylalkanoyl proline derivative, and a phosphonamidate derivative.
Claim 2
Independent Claim
50 words
A method for treating glaucoma or lowering intraocular pressure in a mammalian species, which comprises topically or systemically administering an effective amount of an angiotensin converting enzyme inhibitor selected from the group consisting of a substituted proline derivative, a carboxyalkyl dipeptide derivative, a phosphinylalkanoyl proline derivative, and a phosphonamidate derivative.
Claim 3
Dependent Claim
18 words
The method as defined in claim 1 wherein said angiotensin converting enzyme inhibitor is administered orally or parenterally.
Claim 4
Dependent Claim
16 words
The method as defined in claim 1 wherein said angiotensin converting enzyme inhibitor is administered topically.
Claim 5
Dependent Claim
21 words
The method as defined in claim 1 wherein said angiotensin converting enzyme inhibitor is admixed with a pharmaceutically acceptable carrier therefor.
Claim 6
Dependent Claim
18 words
The method as defined in claim 1 wherein said angiotensin converting enzyme inhibitor is a substituted proline derivative.
Claim 7
Dependent Claim
18 words
The method as defined in claim 1 wherein said angiotensin converting enzyme inhibitor is a carboxyalkyl dipeptide derivative.
Claim 8
Dependent Claim
18 words
The method as defined in claim 1 wherein said angiotensin converting enzyme inhibitor is a phosphinylalkanoyl proline derivative.
Claim 9
Dependent Claim
17 words
The method as defined in claim 1 wherein said angiotensin converting enzyme inhibitor is a phosphonamidate derivative.
Claim 10
Dependent Claim
15 words
The method as defined in claim 1 wherein said angiotensin converting enzyme inhibitor is captopril.
Claim 11
Dependent Claim
17 words
The method as defined in claim 1 wherein said angiotensin converting enzyme inhibitor has the structure ##STR38##
Claim 12
Dependent Claim
19 words
The method as defined in claim 1 wherein said angiotensin converting enzyme inhibitor is 1-[N-[hydroxy(4-phenylbutyl)phosphinyl]-2-alanyl]-L-proline or its disodium salt.
Claim 13
Dependent Claim
31 words
The method as defined in claim 1 wherein the angiotensin converting enzyme inhibitor is administered in the form of tablets, capsules, by injection or topically by sterile solution or ophthalmic insert.
Claim 14
Dependent Claim
30 words
The method as defined in claim 1 wherein the angiotensin converting enzyme inhibitor is captopril and is administered systemically in an amount of from about 8 to about 500 mg.
Claim 15
Dependent Claim
30 words
The method as defined in claim 1 wherein the angiotensin converting enzyme inhibitor is captopril and is administered topically in an amount of from about 0.001 to about 5 mg.
References Cited (Backward Citations)
US3873618A
Cited
US3711602A
Cited
US4179517A
Cited
US4105776A
Cited
US4127674A
Cited
US4149007A
Cited
US4132847A
Cited
US4156010A
Cited
US4152450A
Cited
US4152451A
Cited
US4197301A
Cited
US4168267A
Cited
EP0012401A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-04-10 | 1987-10-10 | 1988-04-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-04-10 | 1991-10-10 | 1992-04-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-04-10 | 1995-10-10 | 1996-04-10 | $7700.00 | Window Closed / Lapsed |